Clinical Trial Update: Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating LAENNEC (human placenta hydrolysate) for chronic liver disease has completed Part A safety/tolerability and Part B dose-optimization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease

Drugs mentioned

• LAENNEC (Human placenta hydrolysate)

Snippet

Sponsor: Green Cross Wellbeing | Conditions: Chronic Liver Disease | Phase 2 | Status: COMPLETED